
- Oncology NEWS International Vol 11 No 4
- Volume 11
- Issue 4
Two Lymphoma Foundations Merge to Form the Lymphoma Research Foundation
LOS ANGELES-The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.
LOS ANGELESThe Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.
By reducing duplicative administrative and program costs, the new foundation expects to be able to enhance its services to patients, caregivers, and health care professionals.
LRFA and CFL have a collective 17 years of experience and have funded more than $7 million in lymphoma research. The new LRF will continue to fund basic, translational, and clinical research projects at the fellow and junior faculty levels.
The new foundation has offices in Los Angeles, focusing on patient services and educational and support programs, and New York, focusing on research grants, public policy and advocacy, finance and development, and professional education. More information is available online at
Articles in this issue
over 23 years ago
Virtual Shared Specimen Resource ‘Essential’over 23 years ago
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cellsover 23 years ago
Letrozole Superior to Tamoxifen in Metastatic Breast Cancerover 23 years ago
S-8184 Paclitaxel Emulsion Promising in Phase I Studyover 23 years ago
HIV+ Veterans Have Higher Rates of Unusual Cancersover 23 years ago
Online Breast Cancer Support Groups Beneficialover 23 years ago
Survival Benefit With Capecitabine/Docetaxelover 23 years ago
FDA Approves Zometa for Cancer-Related Bone ComplicationsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































